Biodexa Pharmaceuticals Plc — Investor Relations & Filings

Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing a pipeline of treatments for diseases with high unmet medical needs. The company's lead candidate, eRapa™, is a proprietary oral formulation of rapamycin being advanced for a Phase 3 trial in familial adenomatous polyposis (FAP), a rare genetic disorder that leads to colorectal cancer. The eRapa™ formulation is designed using nanotechnology to improve the drug's bioavailability and provide more consistent pharmacokinetics. The development pipeline also includes Tolimidone, a potential first-in-class lyn kinase inhibitor for the treatment of type 1 diabetes, and other programs targeting primary and metastatic brain cancers.